The agenda for Arrowhead’s 2010 Personalized Medicine Partnerships Conference, which is set to take place on February 22-24, 2010 in Philadelphia, has been announced. At this three day conference we will highlight key issues in forming partnerships and engage the best speakers to share their experiences.
Minneapolis, MN (PRWEB) November 6, 2009 -- The agenda for Arrowhead’s 2010 Personalized Medicine Partnerships Conference, which is set to take place on February 22-24, 2010 in Philadelphia, has been announced. At this three day conference we will highlight key issues in forming partnerships and engage the best speakers to share their experiences.
Current headlines coming out of Washington suggest that personalized medicine has taken on a level of importance heretofore unseen. As federal funding for comparative effectiveness research and support for personalized medicine from the NIH seems likely, pharmaceutical companies and molecular diagnostics companies increasingly need one another to advance their clinical programs and prove the value of this new healthcare paradigm to both governments and the insurance industry.
Speakers at Arrowhead’s 2009 Personalized Medicine Conference discussed the potential personalized medicine has to revolutionize medical care by utilizing an improved understanding of genetics and molecular biology to allow for better diagnostic tests, more precise diagnoses, greater predictability of disease course, and improved patient safety by selecting not only the right drug for a patient but also the proper dosage to reduce adverse effects.
This year’s conference will focus on the importance of partnerships in advancing the field of personalized medicine on a global scale. Key issues to be discussed at this conference include:
- what pharmaceutical and diagnostic companies are looking for in a partner
- partnering challenges that arise within the realm of contractual negotiations, IP protection, regulatory affairs and commercialization
- benefits of partnerships, including more effective, efficient and safer clinical trials
- how and when to start a relationship, ie. discovery, clinical, post-commercialization?
- the risks of partnering
Conference attendees will come away with a better understanding of the following topics related to personalized medicine and partnerships:
- Partnering models
- Early discovery partnerships
- Value in partnering
- Intellectual property control
- Reimbursement systems and policies
- Clinical development of personalized therapies and companion diagnostics
- Marketing/commercialization of personalized medicine
- Financing of personalized medicine
- Regulatory approaches
Key Speakers at this year’s conference include:
- Christopher Austin, MD, Director, NIH Chemical Genomics Center, National Human Genome Institute
- Stafford O'Kelly, President, Abbott Molecular
- Elizabeth Mansfield, Ph.D., Sr. Director, Genomics and Personalized Medicine, FDA Office of the Commissioner
- Cecilia Schott, PharmD., MBA, Business Development Director, Personalized Healthcare, Strategic Planning and Business Development, AstraZeneca
- Linda Egger, Ph.D., Director, Scientific Liaison, Merck & Co.
- Patrick Terry, CEO, Technic Solutions, Co-Founder, Genomic Health, Founder, Personalized Medicine Coalition
- William Welch, Former Sr. Vice President, Chief Commercial Officer, Monogram Biosciences (LabCorp)
- John A. Norris, JD, MBA, Former Chief Operating Officer, FDA, Chairman and Chief Executive Officer, Norris Capital, Inc., Chief Operating Officer, Health Discovery Corporation
- Stephen Barnhill, MD, Chairman and Chief Executive Officer, Health Discovery Corporation
- Mara G. Aspinall, President and CEO, On-Q-ity, Vice Chairman, Personalized Medicine Coalition, former President, Genzyme Genetics
For the complete list of speakers as well as the agenda, please visit www.personalizedmedicinepartnerships.com or call 1-312-244-3703.
# # #
Read the full story at http://www.prweb.com/releases/2009/11/prweb3163644.htm.
Copyright©2009 Vocus, Inc.
All rights reserved